• 1
    Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990; 50: 788794.
  • 2
    Parker RJ, Gill I, Tarone R. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 1991; 12: 12538.
  • 3
    Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 2005; 23: 43819.
  • 4
    Reed E, Ozols RF, Tarone R. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84: 50248.
  • 5
    Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 225660.
  • 6
    Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 2007; 92: 150512.
  • 7
    Fisch MJ, Howard KL, Einhorn LH. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 1996; 2: 10636.
  • 8
    Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 2003; 9: 446574.
  • 9
    Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 134660.
  • 10
    Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD. Standard chemotherapy compared with high-dose chemoradiotherapy: final results of Phase III US Intergroup Trial S9321 for Multiple Myeloma. J Clin Oncol 2006; 24: 92936.
  • 11
    Child JA, Morgan GJ, Davies EE, Bell SE, Hawkins K. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 187583.
  • 12
    Edler M, Jakubowski N, Linscheid M. Quantitative determination of melphalan DNA adducts using HPLC inductively coupled mass spectrometry. J Mass Spectrom 2006; 41: 50716.
  • 13
    Balcome S, Park S, Quirk Dorr DR, Hafner L, Phillips L, Tretyakova N. Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards. Chem Res Toxicol 2004; 17: 95062.
  • 14
    Hansson J, Lewensohn R, Ringborg U, Nilsson B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug induced cytotoxicity in human melanoma cells. Cancer Res 1987; 47: 26317.
  • 15
    Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 31725.
  • 16
    Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 30720.
  • 17
    Episkopou H, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL. The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. Mutat Res 2011; 714: 7887.
  • 18
    Grimaldi KA, McGurk CJ, McHugh PJ, Hartley JA. PCR-based methods for detecting DNA damage and its repair at the sub-gene and single nucleotide levels in cells. Mol Biotechnol 2002; 20: 18196.
  • 19
    Van Houten B, Cheng S, Chen Y. Measuring gene-specific nucleotide excision repair in human cells using quantitative amplification of long targets from nanogram quantities of DNA. Mutat Res 2000; 460: 8194.
  • 20
    Jennerwein MM, Eastman A. A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. Nucleic Acids Res 1991; 19: 620914.
  • 21
    Kalinowski DP, Illenye S, Van Houten B. Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay. Nucleic Acids Res 1992; 20: 348594.
  • 22
    Grimaldi KA, Bingham JP, Souhami RL, Hartley JA. DNA damage by anticancer agents and its repair: mapping in cells at the subgene level with quantitative polymerase chain reaction. Anal Biochem 1994; 222: 23642.
  • 23
    Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 5149.
  • 24
    Chen X, Cullinane C, Gray PJ, Phillips DR. DNA damage by nitrogen mustard in a gene containing multiple Sp1-binding sites. Mutat Res 1999; 445: 4554.
  • 25
    Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 111523.
  • 26
    Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 88697.
  • 27
    Sfikakis PP, Souliotis VL, Akbar AN, Katsilambros N, Hoffbrand V, Panayiotidis P. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A. Hum Immunol 1996; 50: 1216.
  • 28
    Thomas D, Morton AG, Bohr VA, Sankar A. General method for quantifying base adducts in specific mammalian genes. Proc Natl Acad Sci USA 1988; 85: 37237.
  • 29
    Wang Y-C, Lee P-J, Shih C-M, Chen H-Y, Lee C-C, Chang Y-Y. Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Anal Biochem 2003; 319: 20615.
  • 30
    Oshita F, Eastman A. Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction. Oncol Res 1993; 5: 1118.
  • 31
    Tilby MJ, McCartney H, Gould KA, O'Hare CC, Hartley JA, Hall AG, Golding BT, Lawley PD. A monofunctional derivative of melphalan: preparation, DNA alkylation products, and determination of the specificity of monoclonal antibodies that recognize melphalan-DNA adducts. Chem Res Toxicol 1998; 11: 11628.
  • 32
    Husain K, Whitworth C, Rybak LP. Time response of carboplatin-induced nephrotoxicity in rats. Pharmacol Res 2004; 50: 291300.
  • 33
    Bingham JP, Hartley JA, Souhami RL, Grimaldi KA. Strand-specific measurement of cisplatin-induced DNA damage and repair using quantitative PCR. Nucleic Acids Res 1996; 24: 9879.
  • 34
    Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 1988; 22: 34852.